title: Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study.
abstract: No study has been published yet in the Arab world regarding response and outcome of imatinib in patients with chronic myeloid leukemia (CML). This study evaluated a total of 122 patients with CML treated with imatinib between 2001 and 2012. Survival, hematologic, cytogenetic and molecular responses and adverse events were assessed. The 5-year overall survival (OS), event free survival (EFS) and progression-free survival (PFS) rates were: 95.4 ± 2.3%, 81.4 ± 4.6% and 90.8 ± 3.2%, respectively. Significant differences in OS (p = 0.001), EFS (p = 0.001) and PFS (p = 0.001) were noted when patients were stratified by cytogenetic response. Survival by Sokal risk groups was not significant (p = 0.293). Complete hematologic response was achieved in 94 patients (93.1%), cytogenetic response in 84 (83.2%), major molecular response in 62 (61.4%) and complete molecular response in 34 (33.7%). This article presents the first evidence on the effectiveness of imatinib in patients with CML from Saudi Arabia and highlights similarities and differences in response patterns in published studies.
authors: Pathology and Laboratory Medicine.
authors: Enaam
authors: E
authors: Alsobhi
authors: Mohammed Burhan
authors: MB
authors: Abrar
authors: Mohammed
authors: M
authors: Abdelaal
authors: Ahmed
authors: A
authors: Alsaeed
authors: Ahmed
authors: A
authors: Absi
authors: Zayed
authors: Z
authors: Alzahrani
authors: Ihab
authors: I
authors: El-Hemaidi
authors: Mohammed Ali
authors: MA
authors: Alshehri
authors: Ashraf
authors: A
authors: Warsi
authors: Safaa
authors: S
authors: Bayashoot
authors: Heba
authors: H
authors: Hashem
authors: Anas
authors: A
authors: Merdad
authors: Suhaib
authors: S
authors: Radi
authors: Hanadi
authors: H
authors: Shiekhi
authors: Abdulfattah
authors: A
authors: Al-Amri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D018572:Disease-Free Survival; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D012529:Saudi Arabia; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate
keywords: Chronic myeloid leukemia; cytogenetic; imatinib; molecular; overall survival; variant Ph translocations